Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: A case report

doi:10.4251/wjgo.v15.i10.1829

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3830)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

WORD

HTML

2003

Figures (1-1)

229

Tables (1-1)

198

Sum=2538

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

231

Download

418

Sum=649

Publishing Process of This Article

Item

Count

Browse

182

Download

301

Sum=483

Oct 15, 2023 (publication date) through Nov 27, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastrointest Oncol. Oct 15, 2023; 15(10): 1829-1834
Published online Oct 15, 2023. doi: 10.4251/wjgo.v15.i10.1829

Open in New Tab Full Size Figure Download Figure

Figure 1 Serial cell-free DNA analyses and carcinoembryonic antigen levels over time. Osimertinib was initiated in February 2022, and imaging in April 2022 confirmed treatment response with a decrease in size of the hepatic metastases. CEA: Carcinoembryonic antigen; CEGFR: Epidermal growth factor receptor; VAF: Variant allele frequency.

Citation: Buzard B, Douglass L, Gustafson B, Buckley J, Roth M, Kujtan L, Bansal D. Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: A case report. World J Gastrointest Oncol 2023; 15(10): 1829-1834
URL: https://www.wjgnet.com/1948-5204/full/v15/i10/1829.htm
DOI: https://dx.doi.org/10.4251/wjgo.v15.i10.1829